Skip to main
FEMY
FEMY logo

Femasys (FEMY) Stock Forecast & Price Target

Femasys (FEMY) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Femasys Inc. is positioned for significant revenue growth with the anticipated commercialization of its FemBloc product in Europe starting in the second half of 2025 or the first half of 2026, following recent EU approval. The establishment of strategic partnerships with Spanish distributors enhances Femasys's market entry capabilities and demonstrates a solid foundation for expansion. Additionally, the promising initial results of FemBloc, showcasing a favorable safety profile compared to traditional options, underscore its potential impact in the women's healthcare market.

Bears say

Femasys Inc faces significant risks that cast a negative outlook on its stock, including potential safety issues emerging from clinical or preclinical programs and less-than-expected efficacy from its studies, which could impact investor confidence. Additionally, the company may encounter greater commercial competition for its products and regulatory concerns that could hinder the development and commercialization of its offerings. Furthermore, Femasys has substantial financing requirements, projecting a cash runway only into mid-2025 and necessitating about $80 million in additional funding through 2037, which raises concerns about its financial sustainability and operational viability.

Femasys (FEMY) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Femasys (FEMY) Forecast

Analysts have given Femasys (FEMY) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Femasys (FEMY) has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Femasys (FEMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.